ArticleNederlands tijdschrift voor geneeskunde2015
[Efavirenz and risk of suicide in HIV patients].
Article in Nederlands tijdschrift voor geneeskunde, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Comment on
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Efavirenz is widely used as part of combination antiretroviral therapy in HIV-infected patients. Central nervous system adverse effects are the most important reason for discontinuation of this drug. A recent combined analysis of phase III data showed a two-fold increased risk of suicidal ideation or suicide attempts, when compared with non-efavirenz-containing regimens. This commentary discusses the data from this analysis, tries to explain these observations and the implications for clinical practice, and puts them into perspective in relation to efavirenz's prominent position as a first-line drug for the treatment of HIV infection.
Indexed as
Identifiers
25650033What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.